Gene therapy strategies for the treatment of spinal cord injury

Ther Deliv. 2014 May;5(5):591-607. doi: 10.4155/tde.14.20.

Abstract

Spinal cord injury is a complex pathology often resulting in functional impairment and paralysis. Gene therapy has emerged as a possible solution to the problems of limited neural tissue regeneration through the administration of factors promoting axonal growth, while also offering long-term local delivery of therapeutic molecules at the injury site. Of note, gene therapy is our response to the requirements of neural and glial cells following spinal cord injury, providing, in a time-dependent manner, growth substances for axonal regeneration and eliminating axonal growth inhibitors. Herein, we explore different gene therapy strategies, including targeting gene expression to modulate the presence of neurotrophic growth or survival factors and increase neural tissue plasticity. Special attention is given to describing advances in viral and non-viral gene delivery systems, as well as the available routes of gene delivery. Finally, we discuss the future of combinatorial gene therapies and give consideration to the implementation of gene therapy in humans.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Dependovirus / genetics
  • Fibroblasts / metabolism
  • Genetic Therapy*
  • Humans
  • Neural Stem Cells / metabolism
  • Simplexvirus / genetics
  • Spinal Cord Injuries / therapy*